



## Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019

May 6, 2019

EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, May 14, 2019, at 8:00 A.M. ET to report first quarter 2019 financial results and to discuss recent business updates.

To access the live conference call, please dial 1-866-930-5579 (domestic) or 1-409-216-0606 (international) and refer to conference ID 8758664. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at <https://ir.aptinyx.com>. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

### About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

### Forward-Looking Statements

*Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company's business plans and objectives, including future plans or expectations for the company's product candidates, therapeutic effects of the company's product candidates, expectations regarding the design, implementation, timing, and success of its current and planned clinical studies, the timing for the company's receipt of data from its clinical studies, expectations regarding its preclinical development activities, and expectations regarding its uses and sufficiency of capital. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company's product candidate development activities and planned clinical studies; the company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the company's estimates regarding expenses, future revenue, and capital requirements, and other financial results; as well as those risks and uncertainties set forth in the company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.*

### Investor & Media Contact:

Nick Smith  
Aptinyx Inc.  
[ir@aptinyx.com](mailto:ir@aptinyx.com) or [corporate@aptinyx.com](mailto:corporate@aptinyx.com)  
847-871-0377



Source: Aptinyx Inc.